• Type:
  • Category:

BRAIN Biotech AG Financial Results H1 2022 | Highlights, ESG Commitment, and Mid-Term Targets with IR



IR Michael Schneiders provides an overview of Brain Biotech AG’s H1-22 Highlights, PHA121, Incubator Exits, and more in this financial results presentation. He highlights the Q2-Highlights and the company’s commitment to ESG+. Michael also shares five key points related to ESG+ and the company’s targets for 2032/2050.


He discusses the ESG Opportunity and the Brain Incubator, which includes exciting projects like the Urban Mining Project and Genome Editing. Michael analyses the H1 2021/22 Financial Highlights, including cash and cash flow, long-term revenue growth trajectory, and the impact of Covid, Supply Chain, and Inflation.


Finally, Michael concludes the presentation by providing FY21/22 Guidance and Mid-Term Targets for Brain Biotech AG. Overall, this presentation is an excellent resource for anyone interested in learning more about Brain Biotech AG and its financial performance, ESG commitments, and prospects.

Company Profile

BRAIN Biotech AG (“BRAIN”) is a leading European specialist in industrial biotechnology. As a technology provider and developer of bio-based products and solutions for nutrition, health and the environment, the company supports the biologization of industry and contributes to a more sustainable economy. BRAIN is the parent company of the BRAIN Group. Two pillars form BRAIN Group’s business: The BioScience segment includes contract research for renowned industrial partners as well as an incubator for the development of the company’s own highly innovative products. In the BioIndustrial segment, the company focuses on specialty business in the production and refinement of enzymes, microorganisms and bioactive natural products and the respective distribution.


The BRAIN Group maintains its own diverse collection of natural resources: the BRAIN Bioarchive comprises microorganisms, genetic material and natural substances. Based on this collection and with a comprehensive technology portfolio, BRAIN addresses technological challenges and develops bio-based products and solutions that are already successfully employed in the industry. The BRAIN Group has its own production facilities in Germany, UK and the US, which together with the associated biotechnological production expertise, complete the value chain within the Group.


As a Participant of the United Nations Global Compact, BRAIN Biotech AG is committed to aligning strategies and operations with universal principles on human rights, labour, environment and anti-corruption, and take actions that advance societal goals.


Since its IPO in 2016, BRAIN Biotech AG has been listed in the Prime Standard of the Frankfurt Stock Exchange (ISIN DE0005203947 / WKN 520394).

BRAIN Biotech AG

Darmstaedter Strasse 34-36
64673 Zwingenberg, Germany

phone +49 6251 9331 86


  • Brain at a Glance
  • Group Overview
  • Q2-Highlights
  • ESG+: 5 Key Points
  • ESG+ Targets 2032/2050
  • The ESG Opportunity
  • Brain Incubator
  • Urban Mining Project
  • Genome Editing
  • H1 2021/22 Financial Highlights
  • Cash & Cash Flow
  • Long-Term Revenue Growth Trajectory
  • Covid, Supply Chain and Inflation
  • FY21/22 Guidance, Mid-Term Targets



Michael Schneiders
IR | BRAIN Biotech AG



This publication is for informational purposes only and should not be considered investment advice. By using this website, you agree to the terms and conditions outlined in the legal pages at www.seat11a.com/legal/

More Company Presentations

More Elevator Pitches

Reviews for BRAIN Biotech AG Financial Results H1 2022 | Highlights, ESG Commitment, and Mid-Term Targets with IR

There are currently no reviews for BRAIN Biotech AG Financial Results H1 2022 | Highlights, ESG Commitment, and Mid-Term Targets with IR
Scroll to top